Study provides confidence in timeliness and sensitivity of AusVaxSafety

A new simulation study on Australia’s leading active vaccine safety surveillance system, AusVaxSafety, has been released that shows that the system is robust and would have detected a vaccine safety signal had it been operating in 2010 when there was an unprecedented number of febrile seizures in young children associated with one specific influenza vaccine brand, Fluvax (CSL Biotherapies). Fluvax was subsequently prohibited for use in children.

Read more on AusVaxSafety website.